Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

If the Covid month marked a growth while for virtual fitness corporations, 2024 used to be the reckoning.

In a 12 months that noticed the Nasdaq soar 32%, surpassing 20,000 for the primary while this occasion, fitness tech suppliers in large part suffered. Of 39 people virtual fitness corporations analyzed by way of GWN, more or less two-thirds are ill for the 12 months. Others at the moment are into bankruptcy.

There have been some breakout stars, like Hims & Hers Fitness, which used to be buoyed by way of the luck of its pervasive unutilized weight reduction providing and its place within the GLP-1 craze. However that used to be an exception.

Year there have been some company-specific demanding situations within the business, total it used to be a “year of inflection,” in line with Scott Schoenhaus, an analyst at KeyBanc Capital Markets overlaying health-care IT corporations. Trade fashions that seemed set to crack out all over the pandemic haven’t all labored as deliberate, and corporations have needed to refocus on profitability and a extra muted enlargement shape.

“The pandemic was a huge pull forward in demand, and we’re facing those tough, challenging comps,” Schoenhaus advised GWN in an interview. “Growth clearly slowed for most of my names, and I think employers, payers, providers and even pharma are more selective and more discerning on digital health companies that they partnered with.” 

In 2021, virtual fitness startups raised $29.1 billion, blowing future all earlier investment data, in line with a record from Rock Fitness. Nearly two accumulation virtual fitness corporations went people thru an preliminary people providing or particular function acquisition corporation, or SPAC, that 12 months, up from the former report of 8 in 2020. Cash used to be pouring into subject matters that performed into faraway paintings and faraway fitness as buyers appeared for enlargement with rates of interest caught similar 0.

However because the worst waves of the pandemic subsided, so did the insatiable call for for unutilized virtual fitness gear. It’s been a impolite awakening for the sphere.  

“What we’re still going through is an understanding of the best ways to address digital health needs and capabilities, and the push and pull of the current business models and how successful they may be,” Michael Cherny, an analyst at Leerink Companions, advised GWN. “We’re in a settling out period post Covid.”

Progyny, which deals advantages answers for fertility and community making plans, is ill greater than 60% 12 months to future. Teladoc Fitness, which as soon as ruled the virtual-care length, has dropped 58% and is 96% off its 2021 prime.

When Teladoc obtained Livongo in 2020, the corporations had a mixed endeavor price of $37 billion. Teladoc’s marketplace cap now sits at underneath $1.6 billion.

GoodRx, which deals worth transparency gear for recoveries, is ill 33% 12 months to future. 

Schoenhaus says many corporations’ estimates have been too prime this 12 months.

Progyny decrease its full-year earnings steerage in each and every profits record in 2024. In February, Progyny used to be predicting $1.29 billion to $1.32 billion in annual earnings. By way of November, the length used to be all the way down to $1.14 billion to $1.15 billion.

GoodRx additionally time and again slashed its full-year steerage for 2024. What used to be $800 million to $810 million in Would possibly shrank to $794 million by way of the November.

In Teladoc’s first-quarter record, the corporate stated it anticipated full-year earnings of $2.64 billion to $2.74 billion. The corporate withdrew its outlook in its moment quarter, and reported consecutive year-over 12 months declines.

“This has been a year of coming to terms with the growth outlook for many of my companies, and so I think we can finally look at 2025 as maybe a better year in terms of the setups,” Schoenhaus stated.  

Year overzealous forecasting tells a part of the virtual fitness tale this 12 months, there have been some noteceable stumbles at explicit corporations. 

Dexcom, which makes gadgets for diabetes and glucose control, is ill greater than 35% 12 months to future. The reserve tumbled greater than 40% in July – its steepest abatement ever – next the corporate reported disappointing second-quarter effects and issued susceptible full-year steerage. 

CEO Kevin Sayer attributed the demanding situations to a restructuring of the gross sales staff, fewer unutilized shoppers than anticipated and decrease earnings in keeping with person. Following the record, JPMorgan Chase analysts marveled at “the magnitude of the downside” and the truth that it “appears to mostly be self-inflicted.” 

Genetic trying out corporation 23andMe had a specifically tough 12 months. The corporate went people by the use of a SPAC in 2021, valuing the industry at $3.5 billion, next its at-home DNA trying out kits skyrocketed in reputation. The corporate is now use lower than $100 million and CEO Anne Wojcicki is attempting to stock it afloat.

In September, all seven free administrators resigned from 23andMe’s board, mentioning disagreements with Wojcicki concerning the “strategic direction for the company.” Two months after, 23andMe stated it deliberate to decrease 40% of its staff and shutter its therapeutics industry as a part of a restructuring plan. 

Wojcicki has time and again stated she intends to tug 23andMe non-public. The reserve is ill greater than 80% 12 months to future. 

Virtual fitness’s shining spots

Traders in Hims & Hers had a a lot better 12 months.

Stocks of the direct-to-consumer market are up greater than 200% 12 months to future, pushing the corporate’s marketplace cap to $6 billion, because of hovering call for for GLP-1s. 

Hims & Hers started prescribing compounded semaglutide thru its platform in Would possibly next launching a unutilized weight reduction program overdue closing 12 months. Semaglutide is the lively factor in Novo Nordisk‘s blockbuster recoveries Ozempic and Wegovy, which will price round $1,000 a occasion with out insurance coverage. Compounded semaglutide is a less expensive, personalized backup to the emblem medicine and may also be produced when the brand-name therapies are in insufficiency.

Hims & Hers will most probably need to cope with dynamic provide and regulatory environments upcoming 12 months, however even sooner than including compounded GLP-1s to its portfolio, the corporate stated in its February profits name that it expects its weight reduction program to deliver in additional than $100 million in earnings by way of the tip of 2025. 

Doximity, a virtual platform for clinical pros, additionally had a powerful 2024, with its reserve worth greater than doubling. The corporate’s platform, which for years has been likened to a LinkedIn for medical doctors, lets in clinicians to stick wave on clinical information, govern bureaucracy, to find referrals and perform telehealth appointments with sufferers. 

Doximity essentially generates earnings thru its hiring answers, telehealth gear and advertising choices for shoppers like pharmaceutical corporations.

Leerink’s Cherny stated Doximity’s luck may also be attributed to its incline running style, in addition to the “differentiated mousetrap” it’s created on account of its succeed in into the doctor community. 

“DOCS is a rare company in healthcare IT as it is already profitable, generates strong incremental margins, and is a steady grower,” Leerink analysts, together with Cherny, wrote in a November observe. The company raised its worth goal at the reserve to $60 from $35. 

Every other standout this 12 months used to be Oscar Fitness, the tech-enabled insurance coverage corporation co-founded by way of Thrive Capital Control’s Joshua Kushner. Its stocks are up just about 50% 12 months to future. The corporate helps more or less 1.65 million participants and plans to extend to round 4 million by way of 2027. 

Oscar confirmed robust earnings enlargement in its third-quarter record in November. Gross sales climbed 68% from a 12 months previous to $2.4 billion.

Moreover, two virtual fitness corporations, Waystar and Tempus AI, took the bounce and went people in 2024. 

The IPO marketplace has been in large part dormant since overdue 2021, when hovering inflation and emerging rates of interest driven buyers out of possibility. Few generation corporations have long past people since later, and deny virtual fitness corporations held IPOs in 2023, in line with a record from Rock Fitness. 

Waystar, a health-care fee tool seller, has perceivable its reserve soar to $36.93 from its IPO worth of $21.50 in June. Tempus, a precision drugs corporation, hasn’t fared as smartly. It’s reserve has slipped to $34.91 from its IPO worth of $37, additionally in June.

“Hopefully, the valuations are more supportive of opportunities for other companies that have been lingering in the background as private companies for the last several years.” Schoenhaus stated. 

Out with the worn

A number of virtual fitness corporations exited the people markets fully this 12 months. 

Cue Fitness, which made Covid exams and counted Google as an early buyer, and Higher Therapeutics, which impaired virtual therapeutics to regard cardiometabolic situations, each shuttered operations and delisted from the Nasdaq. 

Earnings cycle control corporation R1 RCM used to be obtained by way of TowerBrook Capital Companions and Clayton, Dubilier & Rice in an $8.9 billion trade in. In a similar fashion, Altaris purchased Sharecare, which runs a digital fitness platform, for more or less $540 million.

Commure, a non-public corporation that deals gear for simplifying clinicians’ workflows, obtained clinical AI scribing corporation Augmedix for approximately $139 million.

“There was a lot of competition that entered the marketplace during the pandemic years, and we’ve seen some of that being flushed out of the markets, which is a good thing,” Schoenhaus stated.

Cherny stated the sphere is adjusting to a post-pandemic duration, and virtual fitness corporations are working out their position.

“We’re still cycling through what could be almost termed digital health 1.1 business models,” he stated. “It’s great to say we do things digitally, but it only matters if it has some approach toward impacting the ‘triple aim’ of health care: better care, more convenient, lower cost.”